tiprankstipranks
Advertisement
Advertisement

IKT Stock Latest News

Buy Rating on IKT-001: De-Risked Late-Stage PAH Program with Adaptive Phase 3 Design and Solid Financial Runway
RatingsBuy Rating on IKT-001: De-Risked Late-Stage PAH Program with Adaptive Phase 3 Design and Solid Financial Runway
10d ago
IKT
Inhibikase Therapeutics: Phase 3 IKT-001 PAH Program and De-Risked Imatinib-Based Efficacy Drive Buy Rating and $8 Target
PremiumRatings
Inhibikase Therapeutics: Phase 3 IKT-001 PAH Program and De-Risked Imatinib-Based Efficacy Drive Buy Rating and $8 Target
10d ago
IKT
Inhibikase Begins Pivotal Phase 3 Trial in PAH
PremiumCompany Announcements
Inhibikase Begins Pivotal Phase 3 Trial in PAH
11d ago
8K
IKT
Inhibikase Therapeutics enrolls first patient in IMPROVE-PAH study
PremiumThe Fly
Inhibikase Therapeutics enrolls first patient in IMPROVE-PAH study
11d ago
IKT
IKT Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
IKT Upcoming Earnings Report: What to Expect?
25d ago
IKT
Inhibikase Therapeutics initiated with a Buy at Ladenburg
PremiumThe FlyInhibikase Therapeutics initiated with a Buy at Ladenburg
1M ago
IKT
Inhibikase Therapeutics initiated with a Buy at Ladenburg
Premium
The Fly
Inhibikase Therapeutics initiated with a Buy at Ladenburg
1M ago
IKT
Buy Rating on Inhibikase Therapeutics Driven by Rival PAH Setback and Pivotal Phase 3 IMPROVE-PAH Trial for IKT-001
Premium
Ratings
Buy Rating on Inhibikase Therapeutics Driven by Rival PAH Setback and Pivotal Phase 3 IMPROVE-PAH Trial for IKT-001
2M ago
IKT
Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks
PremiumMarket News
Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks
2M ago
IKT
WVE
Inhibikase Therapeutics initiated with a Buy at BofA
PremiumThe Fly
Inhibikase Therapeutics initiated with a Buy at BofA
3M ago
IKT
Dynavax, Inhibikase and More: Stocks Trending by Analysts
PremiumWeekend Updates
Dynavax, Inhibikase and More: Stocks Trending by Analysts
4M ago
IKT
DVAX
Inhibikase Therapeutics: Late-Stage IKT-001 PAH Program and De-Risked 505(b)(2) Pathway Support Buy Rating and $8 Target
PremiumRatings
Inhibikase Therapeutics: Late-Stage IKT-001 PAH Program and De-Risked 505(b)(2) Pathway Support Buy Rating and $8 Target
4M ago
IKT
Inhibikase Updates ATM Equity Program to Raise Capital
PremiumCompany AnnouncementsInhibikase Updates ATM Equity Program to Raise Capital
4M ago
8K
IKT
Inhibikase Therapeutics initiated with an Overweight at Cantor Fitzgerald
Premium
The Fly
Inhibikase Therapeutics initiated with an Overweight at Cantor Fitzgerald
4M ago
IKT
Inhibikase Therapeutics: Advancing IKT-001 to Revolutionize PAH Treatment and Capture Multi-Billion-Dollar Market
Premium
Ratings
Inhibikase Therapeutics: Advancing IKT-001 to Revolutionize PAH Treatment and Capture Multi-Billion-Dollar Market
5M ago
IKT
Inhibikase Therapeutics Reports Q3 2025 Financials and Progress
PremiumCompany Announcements
Inhibikase Therapeutics Reports Q3 2025 Financials and Progress
5M ago
IKT
Inhibikase Therapeutics Announces $93.6 Million Stock Offering
PremiumCompany Announcements
Inhibikase Therapeutics Announces $93.6 Million Stock Offering
5M ago
8K
IKT
Inhibikase Therapeutics 46.1M share Spot Secondary priced at $1.45
PremiumThe Fly
Inhibikase Therapeutics 46.1M share Spot Secondary priced at $1.45
5M ago
IKT
Inhibikase Therapeutics TBA Spot Secondary; reoffered at $1.45
PremiumThe Fly
Inhibikase Therapeutics TBA Spot Secondary; reoffered at $1.45
5M ago
IKT
Inhibikase Therapeutics Advances IKT-001 to Phase 3 Study
PremiumCompany AnnouncementsInhibikase Therapeutics Advances IKT-001 to Phase 3 Study
5M ago
8K
IKT
Inhibikase announces common stock and warrants offering, no amount given
Premium
The Fly
Inhibikase announces common stock and warrants offering, no amount given
5M ago
IKT
Inhibikase Therapeutics to advance IKT-001 to Phase 3 clinical study in PAH
Premium
The Fly
Inhibikase Therapeutics to advance IKT-001 to Phase 3 clinical study in PAH
5M ago
IKT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >